Coronary artery restenosis: A paradigm of current treatment approaches

Minerva Cardioangiologica

Volumn 57, Issue 1, 2009, Pages 77-94

  Kiernan, T J ^a   Kiernan, G D ^b   Yan, B P ^c,d  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY COLLEGE DUBLIN   (Ireland)

^c CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^d MONASH UNIVERSITY   (Australia)

Author keywords

Angioplasty; Atherosclerosis; Coronary restenosis; Stents

Indexed keywords

BATIMASTAT; BIOLIMUS; DEXAMETHASONE; EVEROLIMUS; PACLITAXEL; RAPAMYCIN; TACROLIMUS; TITANIUM; TRANILAST; UNCLASSIFIED DRUG; ZOTAROLIMUS;

ATHEROSCLEROSIS; BIOCOMPATIBILITY; BIOSORPTION; CELL THERAPY; CLINICAL TRIAL; CORONARY STENT; DRUG ELUTING STENT; HUMAN; NONHUMAN; RESTENOSIS; REVIEW; TRANSLUMINAL CORONARY ANGIOPLASTY; CORONARY ARTERY DISEASE; ENDOTHELIUM CELL; META ANALYSIS; RANDOMIZED CONTROLLED TRIAL; TRANSPLANTATION; TREATMENT OUTCOME;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ATHEROSCLEROSIS; CLINICAL TRIALS AS TOPIC; CORONARY ARTERY DISEASE; CORONARY RESTENOSIS; DRUG-ELUTING STENTS; ENDOTHELIAL CELLS; HUMANS; META-ANALYSIS AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 67849085072     PISSN: 00264725     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (88)

1. Pauletto P, Sartore S, Pessina AC. Smooth-muscle-cell proliferation and differentiation in neointima formation and vascular restenosis. Clin Sci (Lond) 1994;87:467-79. (Pubitemid 24353458)
2. Cines DB, Pollak ES, Buck CA, Loscalzo J, Zimmerman GA, McEver RP et al. Endothelial cells in physiology and in the pathophysiology of vascular disorders. Blood 1998;91:3527-61. (Pubitemid 28225719)
3. Behrendt D, Ganz P. Endothelial. Endothelial function. From vascular biology to clinical applications. Am J Cardiol 2002;90:40L. (Pubitemid 35379905)
4. Fischman DL, Leon MB, Baim DS, Schatz RA, Savage MP, Penn I et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. N Engl J Med 1994;331:496-501. (Pubitemid 24256752)
5. Serruys PW, de Jaegere P, Kiemeneij F, Macaya C, Rutsch W, Heyndrickx G et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery diseases. N Engl J Med 1994;331:489-95. (Pubitemid 24256751)
6. Cutlip DE, Chauhan MS, Baim DS, Ho KK, Popma JJ, Carrozza JP et al. Clinical restenosis after coronary stenting: perspectives from multicenter clinical trials. J Am Coll Cardiol 2002;40:2082-9.
7. Maier W, Windecker S, Boersma E Meier B. Evolution of percutaneous transluminal coronary angioplasty in Europe from 1992-1996. Eur Heart J. 2001;22:1733-40.
8. Serruys PW, Strauss BH, van Beusekom HM, van der Giessen WJ. Stenting of coronaryarteries: has a modern Pandora's box been opened? J Am Coll Cardiol 1991;17:143B-154B.
9. Costa MA, Foley DP, Serruys PW. Restenosis: the problem and how to deal with it. In: Grech ED, Ramsdale DR, editors. Practical Interventional Cardiology; 2nd edition. London: Martin Dunitz; 2002. p. 279-94.
10. Kastrati A, Schömig A, Dirschinger J, Mehilli J, von Weiser N, Pache J et al. Increased risk of restenosis after placement of gold-coated stents: results of a randomized trial comparing gold-coated with uncoated steel stents in patients with coronary artery disease. Circulation 2000;101:2478-83. (Pubitemid 30366251)
11. Lincoff AM, Topol EJ, Ellis SG. Local drug delivery for the prevention of restenosis: fact, fancy, and future. Circulation 1994;90:2070-84.
12. Costa MA, Simon DI. Molecular basis of restenosis and drug-eluting stents. Circulation 2005;111:2257-73.
13. Regar E, Sianos G, Serruys PW. Stent development and local drug delivery. Br Med Bull 2001;59:227-48. (Pubitemid 34076026)
14. Sousa JE, Costa MA, Abizaid A, Feres F, Seixas AC, Tanajura LF et al. Four-year angiographic and intravascular ultrasound follow-up of patients treated with sirolimus-eluting stents. Circulation 2005;111:2326-9. (Pubitemid 40647068)
15. Meredith IT, Ormiston J, Whitbourn R, Kay IP, Muller D, Popma JJ et al. First-in-human study of the Endeavor ABT-578-eluting phosphorylcholine- encapsulated stent system in de novo native coronary artery lesions: Endeavor I Trial. Eurointervention 2005;1:157-64.
16. Grube E, Sonoda S, Ikeno F, Honda Y, Kar S, Chan C et al. Six- and twelve-month results from first human experience using everolimus-eluting stents with bioabsorbable polymer. Circulation 2004;109:2168-71. (Pubitemid 38625391)
17. Serruys PW, Ong ATL, Piek JJ. A randomized comparison of a durable polymer Everolimus-eluting stent with a bare metal coronary stent: the SPIRIT first trial. Eurointervention 2005;1:58-65.
18. Grube E, Hauptmann K-E, Buellesfeld L, Lim V, Abizaid A. Six-month results of a randomized study to evaluate safety and efficacy of a Biolimus A9 eluting stent with a biodegradable polymer coating. EuroIntervention 2005;1:53-7.
19. Carter AJ, Aggarwal M, Kopia GA, Tio F, Tsao PS, Kolata R et al. Long-term effects of polymer-based, slow-release, sirolimus-eluting stents in a porcine coronary model. Cardiovasc Res 2004;63:617-24. (Pubitemid 39078675)
20. Roiron C, Sanchez P, Bouzamondo A, Lechat P, Montalescot GA. Drug eluting stents: an updated meta-analysis of randomised controlled trials. Heart 2006;92:641.
21. Krucoff MW, Kereiakes DJ, Petersen JL, Mehran R, Hasselblad V, Lansky AJ etal. COSTAR II Investigators Group. A novel bioresorbable polymer paclitaxel-eluting stent for the treatment of single and multivessel coronary disease: primary results of the COSTAR (Cobalt Chromium Stent With Antiproliferative for Restenosis) II study. J Am Coll Cardiol 2008;51:1543-52.
22. van der Giessen WJ, Lincoff AM, Schwartz RS, van Beusekom HM, Serruys PW, Holmes DR Jr et al. Marked inflammatory sequelae to implantation of biodegradable and nonbiodegradable polymers in porcine coronary arteries. Circulation 1996;94:1690-7.
23. Ratner BD. The blood compatibility catastrophe. J Biomed Mater Res 1993;27:283-7.
24. Joner M, Finn AV, Farb A, Mont EK, Kolodgie FD, Ladich E et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol 2006;48:193-202.
25. Nebeker JR, Virmani R, Bennett CL, Hoffman JM, Samore MH, Alvarez J et al. Hypersensitivity cases associated with drug-eluting coronary stents: a review of available cases from the Research on Adverse Drug Events and Reports (RADAR) project. J Am Coll Cardiol 2006;47:175-81.
26. Costa RA, Lansky AJ, Abizaid A, Mueller R, Tsuchiya Y, Mori K et al. Angiographic results of the first human experience with the Biolimus A9 drug-eluting stent for de novo coronary lesions. Am J Cardiol 2006;98:443-6.
27. Ostovan MA, Mollazadeh R, Kojuri J, Mirabadi M. Experience with paclitaxel-eluting Infinnium coronary stents. Asian Cardiovasc Thorac Ann 2008;16:454-8.
28. Mehilli J, Kastrati A, Wessely R, Dibra A, Hausleiter J, Jaschke B et al. Randomized trial of a nonpolymerbased rapamycin-eluting stent versus a polymer-based paclitaxeleluting stent for the reduction of late lumen loss. Circulation 2006;113:273-9.
29. Gershlick A, De Scheerder I, Chevalier B, Stephens-Lloyd A, Camenzind E, Vrints C et al. Inhibition of restenosis with a paclitaxel-eluting, polymer-free coronary stent: the European evaLUation of pacliTaxel Eluting Stent (ELUTES) trial. Circulation 2004;109:487-93.
30. Lansky AJ, Costa RA, Mintz GS, Tsuchiya Y, Midei M, Cox DA et al. Non-polymer-based paclitaxel-coated coronary stents for the treatment of patients with de novo coronary lesions: angiographic follow-up of the DELIVER clinical trial. Circulation 2004;109:1948-54.
31. Lovich MA, Creel C, Hong K, Hwang CW, Edelman ER et al. Carrier proteins determine local pharmacokinetics and arterial distribution of paclitaxel. J Pharm Sci 2001;90:1324-35.
32. Braun-Dullaeus RC, Mann MJ, Dzau VJ. Cell cycle progression: new therapeutic target for vascular proliferative disease. Circulation 1998;98:82-9.
33. Marx SO, Marks AR. Bench to bedside: the development of rapamycin and its application to stent restenosis. Circulation 2001;104:852-5.
34. Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M et al. RAVEL Study Group. Randomized Study with the Sirolimus-Coated Bx Velocity Balloon-Expandable Stent in the Treatment of Patients with de Novo Native Coronary Artery Lesions. N Engl J Med 2002;346:1773-80.
35. Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med, 2003, 349, 1315-23.
36. Lemos PA, Serruys PW, van Domburg RT, Saia F, Arampatzis CA, Hoye A et al. Unrestricted utilization of sirolimus-rluting stents compared with conventional bare stent implantation in the "real world": the Rapamicin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) Registry. Circulation 2004;109:190-5.
37. Meredith IT, Ormiston J, Whitbourn R, Kay IP, Muller D, Popma JJ et al. First-in-human study of the Endeavor ABT-578-eluting phosphorylcholine- encapsulated stent system in de novo native coronary artery lesions: Endeavor I Trial. Eurointervention 2005;1:157-64.
38. Fajadet J, Wijns W, Laarman GJ, Kuck KH, Ormiston J, Münzel T et al. ENDEAVOR II Investigators. Randomized, double-blind, multicenter study of the Endeavor zotarolimus-eluting phosphorylcholine-encapsulated stent for treatment of native coronary artery lesions: clinical and angiographic results of the ENDEAVOR II trial. Circulation. 2006;114:798-806.
39. Kandzari DE, Leon MB, Popma JJ, Fitzgerald PJ, O'Shaughnessy C, Ball MW et al. ENDEAVOR III Investigators. Comparison of zotarolimus-eluting and sirolimus-eluting stents in patients with native coronary artery disease: a randomized controlled trial. J Am Coll Cardiol 2006;48:2440-7.
40. Stone GW, Midei M, Newman W, Sanz M, Hermiller JB, Williams J etal. SPIRIT III Investigators. Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: a randomized trial. JAMA 2008;299:1903-13.
41. Marx SO, Jayaraman T, Go LO, Marks AR. Rapamycin-FKBP inhibits cell cycle regulators of proliferation in vascular smooth muscle cells. Circ Res 1995;76:412-7.
42. Grube E, Hauptmann K, Buellesfeld L, Lim V, Abizaid A. Six-month results of a randomized study to evaluate safety and efficacy of a Biolimus A9 eluting stent with a biodegradable polymer coating. Euro Intervention 2005;1:53-7.
43. Windecker S, Serruys PW, Wandel S, Buszman P, Trznadel S, Linke A et al. Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): a randomised non inferiority trial. Lancet 2008;372:1163-73.
44. Babapulle MN, Joseph L, Belisle P, Brophy JM, Eisenberg MJ. A hierarchical Bayesian meta-analysis of randomised clinical trials of drug-eluting stents. Lancet 2004;364:583-91.
45. Serruys PW. Long-term effects of angiopeptin treatment in coronary angioplasty: reduction of clinical events but not angiographic restenosis. Circulation 1995;92:2759-60.
46. Armstrong J, Gunn J, Arnold N, Malik N, Chan KH, Vick T et al. Angiopeptin-eluting stents: observations in human vessels and pig coronary arteries. J Invasive Cardiol 2002;14:230-8.
47. Kwok OH, Chow WH, Law TC, Chiu A, Ng W, Lam WF et al. First human experience with angiopeptin-eluting stent: a quantitative coronary angiography and three-dimensional intravascular ultrasound study. Catheter Cardiovasc Interv 2005;66:541-6.
48. Berk BC, Gordon JB, Alexander RW. Pharmacologic roles of heparin and glucocorticoids to prevent restenosis after coronary angioplasty. J Am Coll Cardiol 1991;17:111B-117B.
49. Pepine CJ, Hirshfeld JW, Macdonald RG, Henderson MA, Bass TA, Goldberg S et al. A controlled trial of corticosteroids to prevent restenosis after coronary angioplasty. M-HEART Group. Circulation 1990;81:1753-61.
50. Holmes DR Jr, Savage M, LaBlanche JM, Grip L, Serruys PW, Fitzgerald P et al. Results of Prevention of REStenosis with Tranilast and its Outcomes (PRESTO) trial. Circulation. 2002;106(10):1243-50.
51. Li C, Cantor WJ, Nili N, Robinson R, Fenkell L, Tran YL et al. Arterial repair after stenting and the effects of GM6001, a matrix metalloproteinase inhibitor. J Am Coll Cardiol 2002;39:1852-8.
52. Lovdahl C, Thyberg J, Hultgardh-Nilsson A. The synthetic metalloproteinase inhibitor batimastat suppresses injury-induced phosphorylation of MAP kinase ERK1/ERK2 and phenotypic modification of arterial smooth muscle cells in vitro. J Vasc Res 2000;37:345-354.
53. Araujo CM, Rando GA, Mauro MF, Cristovóão SA, Sanchez IS, Salman AA et al. Batimastat-eluting stent implantation for the treatment of coronary artery disease: results of the Brazilian pilot study. Arq Bras Cardiol 2005;84:256-60.
54. Morice MC, Colombo A, Meier B, Serruys P, Tamburino C, Guagliumi G et al. REALITY Trial Investigators. Sirolimus- vs paclitaxel-eluting stents in de novo coronary artery lesions: the REALITY trial: a randomized controlled trial. JAMA 2006;295:895-904.
55. Ong AT, Serruys PW, Aoki J, Hoye A, van Mieghem CA, Rodriguez-Granillo GA. The unrestricted use of paclitaxel- versus sirolimus-eluting stents for coronary artery disease in an unselected population: one-year results of the Taxus-Stent Evaluated at Rotterdam Cardiology Hospital (T-SEARCH) registry. J Am Coll Cardiol 2005;45:1135-41.
56. Moliterno, DJ. Healing Achilles - sirolimus versus paclitaxel. N Engl J Med 2005;353:724-7.
57. Wessely R, Schomig A, Kastrati A. Sirolimus and Paclitaxel on polymer-based drug-eluting stents: similar but different. J Am Coll Cardiol 2006;47:708-14.
58. Finn AV, Kolodgie FD, Harnek J, Guerrero LJ, Acampado E, Tefera K et al. Differential response of delayed healing and persistent inflammation at sites of overlapping sirolimus- or paclitaxel-eluting stents. Circulation 2005;112:270-8.
59. Smith SC Jr, Feldman TE, Hirshfeld JW Jr, Jacobs AK, Kern MJ, King SB 3rd et al. American College of Cardiology/American Heart Association Task Force on Practice Guidelines; ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention. J Am Coll Cardiol 2006;47:e1.
60. Win HK, Caldera AE, Maresh K, Lopez J, Rihal CS, Parikh MA et al. Clinical outcomes and stent thrombosis following off-label use of drug-eluting stents. JAMA 2007;297:2001-9.
61. Ormiston JA, Serruys PW, Regar E, Dudek D, Thuesen L, Webster MW et al. A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB): a prospective open-label trial. Lancet 2008;371:899-907.
62. Erbel R, Di Mario C, Bartunek J, Bonnier J, de Bruyne B, Eberli FR et al. Temporary scaffolding of coronary arteries with bioabsorbable magnesium stents: a prospective, non-randomised multicentre trial. Lancet 2007;369:1869-75.
63. Yadav JS, Roubin GS, Iyer S, Vitek J, King P, Jordan WD, Fisher WS. Elective stenting of the extracranial carotid arteries. Circulation 1997;95:376-81.
64. Iancu A, Lazar A. Carotid artery in-stent restenosis in a patient with contralateral total occlusion, resolved with drug-eluting stenting. J Invasive Cardio 2007;19:275-9.
65. Asahara T, Murohara T, Sullivan A, Silver M, van der Zee R, Li T et al. Isolation of putative progenitor endothelial cells for angiogensis. Science 1997;275:964-7. (Pubitemid 27087709)
66. Asahara T, Masuda H, Takahashi T, Kalka C, Pastore C, Silver M et al. Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circulation Research 1999;85:221-8. (Pubitemid 29377293)
67. Herring M, Gardner A, Glover J. A single-staged technique for seeding vascular grafts with autogenous endothelium. Surgery 1978;84:498-504. (Pubitemid 9033945)
68. Berinyi L, Conte M, Mulligan R. Repopulation of injured arteries with genetically modified endothelial cells. J Vasc Surg 1992;15:932-4.
69. Thompson M, Bud J, Eady S, James R, Bell P. A method to transluminally seed angioplasty sites with endothelial cells using a double balloon catheter. Eur J Vasc Surg 1993;7:113-21. (Pubitemid 23132484)
70. Thompson MM, Budd JS, Eady SL, Hartley G, Early M, James RF et al. Platelet deposition after angioplasty is abolished by restoration of the endothelial cell monolayer. J Vasc Surg 1994;19:478-86. (Pubitemid 24093982)
71. Conte MS, Birinyi LK, Miyata T, Fallon JT, Gold HK, Whittemore AD et al. Efficient repopulation of denuded rabbit arteries with autologous gentically modified endothelial cells. Circulation 1994;23:2161-9. (Pubitemid 24142794)
72. Conte M, Belkin M, Donaldson M, Baum P, Mannick J, Whittemore A. Femorotibial bypass for claudication: do results justify an aggressive approach? J Vasc Surg 1995;21:880-1.
73. Griese DP, Ehsan A, Melo LG, Kong D, Zhang L, Mann MJ et al. Isolation and transplantation of autologous circulating endothelial cells into denuded vessels and prosthetic grafts: implications for cell-based vascular therapy. Circulation 2003;108:2710-5. (Pubitemid 37466815)
74. Kong D, Melo LG, Mangi AA, Zhang L, Lopez-Ilasaca M, Perrella MA et al. Enhanced inhibition of neointimal hyperplasia by genetically engineered endothelial progenitor cells. Circulation 2004;109:1769-75. (Pubitemid 38500680)
75. He T, Smith LA, Harrington S, Nath KA, Caplice NM, Katusic ZS. Transplantation of circulating endothelial progenitor cells restores endothelial function of denuded rabbit carotid arteries. Stroke 2004;35:2378-84. (Pubitemid 39311267)
76. Gulati R, Jevremovic D, Peterson TE, Witt TA, Kleppe LS, Mueske CS et al. Autologous culture-modified mononuclear cells confer vascular protection after arterial injury. Circulation 2003;108:1520-6. (Pubitemid 37176461)
77. Kamihata H, Matsubara H, Nishiue T, Fujiyama S, Tsutsumi Y, Ozono R et al. Implantation of bone marrow mononuclear cells into ischemic myocardium enhances collateral perfusion and regional function via side supply of angioblasts, angiogenic ligands, and cytokines. Circulation 2001;104:1046-52. (Pubitemid 32803883)
78. Werner N, Junk S, Laufs U, Link A, Walenta K, Bohm M et al. Intravenous transfusion of endothelial progenitor cells reduces neointima formation after vascular injury. Circ Res 2003;93:e17-24.
79. Aoki J, Serruys PW, van Beusekom H, Ong AT, McFadden EP, Sianos G et al. Endothelial progenitor cell capture by stents coated with antibody against CD34: the HEALING-FIM (Healthy Endothelial Accelerated Lining Inhibits Neointimal Growth-First In Man) Registry. J Am Coll Cardiol 2005;45:1574-9. (Pubitemid 40704488)
80. Kutryk MJ, Kuliszewski MA, Sandhu R, Fitchett D, Stewart DJ. In vivo endothelial progenitor cell seeding of stented arterial segments and vascular grafts. Circulation 2003;108:2612-6.
81. Anagnostou A, Liu Z, Steiner M, Chin K, Lee ES, Kessimian N et al. Erythropoietin receptor mRNA expression in human endothelial cells. Proc Natl Acad Sci U S A 1994;98:3974-8.
82. Anagnostou A, Lee ES, Kessimian N, Levinson R, Steiner M. Erythropoietin has a mitogenic and positive chemotactic effect on endothelial cells. Proc Natl Acad Sci U S A. 1990;87:5978-82.
83. Carlini RG, Alonzo EJ, Dominguez J, Bianca I, Weisinger JR, Rothstein M et al. Effect of recombinant human erythropoietin on endothelial cell apoptosis. Kidney Int 1999;55:546-83.
84. Beleslin-Cokic BB, Cokic VP, Yu X, Weksler BB, Schechter AN, Noguchi CT. Erythropoietin and hypoxia stimulate erythropoietin receptor and nitric oxide production by endothelial cells. Blood 2004;104:2073-80.
85. Heeschen C, Aicher A, Lehmann R, Fichtischerer S, Vasa M, Urbich C et al. Erythropoietin is a potent physiologic stimulus for endothelial progenitor cell mobilization Blood 2003;102:1340-6.
86. Ribatti D, Presta M, Vacca A, Ria R, Giuliani R, Dell'Era P et al. Human erythropoietin induces a pro-angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo. Blood 1999;93:2627-36.
87. Galeano M, Altavilla D, Cucinotta D, Russo GT, Calo M, Bitto A et al. Recombinant human erythropoietin stimulates angiogenesis and wound healing in the genetically diabetic mouse. Diabetes 2004;53:2509-17.
88. Urao N, Okigaki M, Yamada H, Aadachi Y, Matsuno K, Matsui A et al. Erythropoietin-mobilized endothelial progenitors enhances reendothelialization via akt-endothelial nitric oxide synthase activation and prevents neointimal hyperplasia. Circ Res 2006;98:1405-13.